Dr. Naomi Sacks, BRLS Vice President in our Pharmaceutical Commercialization practice, is a co-author of a study recently published in JAC-Antimicrobial Research. Dr. Sacks and co-authors were interested in characterizing acute, uncomplicated cystitis (AUC) in Japan. They used the Japanese Medical Database Centre payer claims database to estimate AUC annual prevalence and characterize AUC patients, treatment patterns, and outcomes. They were particularly interested in AUC recurrence and treatment failure, given both emerging fluroquinolone resistance and inappropriate antibiotic use. They estimated that AUC affects up to 3.9 million women in Japan annually, with approximately 5% of patients experiencing treatment failure and 10% a subsequent recurrence. Further, AUC costs total ¥14 905 (Japanese Yen) per AUC episode. Their study, Prevalence and economic evaluation of acute uncomplicated cystitis in women from Japan: A retrospective cohort study, complements earlier work on treatment failure in uncomplicated UTI in the US.
